Goldman Sachs
PCVX icon

Goldman Sachs’s Vaxcyte PCVX Stock Holding History

Goldman Sachs’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.1M Buy
1,275,036
+196,916
+18% +$10.7M 0.01% 1258
2025
Q4 		$49.7M Buy
1,078,120
+102,743
+11% +$4.6M 0.01% 1513
2025
Q3 		$35.1M Buy
975,377
+40,709
+4% +$1.35M ﹤0.01% 1723
2025
Q2 		$30.4M Sell
934,668
-212,634
-19% -$6.97M ﹤0.01% 1740
2025
Q1 		$43.3M Sell
1,147,302
-1,982,302
-63% -$158M 0.01% 1328
2024
Q4 		$256M Buy
3,129,604
+2,180,353
+230% +$217M 0.04% 421
2024
Q3 		$108M Buy
949,251
+212,512
+29% +$19.2M 0.02% 756
2024
Q2 		$55.6M Buy
736,739
+38,247
+5% +$2.6M 0.01% 1093
2024
Q1 		$47.7M Buy
698,492
+217,373
+45% +$15.1M 0.01% 1198
2023
Q4 		$30.2M Buy
481,119
+52,005
+12% +$2.7M 0.01% 1551
2023
Q3 		$21.9M Sell
429,114
-16,731
-4% -$825K ﹤0.01% 1722
2023
Q2 		$22.3M Sell
445,845
-52,506
-11% -$2.49M ﹤0.01% 1758
2023
Q1 		$18.7M Buy
498,351
+98,987
+25% +$4.2M ﹤0.01% 1869
2022
Q4 		$19.1M Sell
399,364
-88,519
-18% -$3.47M ﹤0.01% 2004
2022
Q3 		$11.7M Buy
487,883
+134,502
+38% +$3.41M ﹤0.01% 2365
2022
Q2 		$7.69M Buy
353,381
+10,830
+3% +$251K ﹤0.01% 2756
2022
Q1 		$8.27M Buy
342,551
+144,074
+73% +$3.15M ﹤0.01% 2877
2021
Q4 		$4.72M Sell
198,477
-47,817
-19% -$1.11M ﹤0.01% 3468
2021
Q3 		$6.25M Buy
246,294
+60,709
+33% +$1.47M ﹤0.01% 3162
2021
Q2 		$4.18M Buy
185,585
+4,485
+2% +$91.8K ﹤0.01% 3501
2021
Q1 		$3.58M Sell
181,100
-114,808
-39% -$2.89M ﹤0.01% 3447
2020
Q4 		$7.86M Buy
+295,908
New +$11M ﹤0.01% 2651
2020
Q3 		– Sell
-87,424
Closed -$2.76M – 5496
2020
Q2 		$2.76M Buy
+87,424
New +$2.81M ﹤0.01% 3225

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's PCVX Position: Q1 2026 in Review

Goldman Sachs increased its Vaxcyte (PCVX) stake by 18% in Q1 2026, buying an estimated $10.7M and bringing the position to 1,275,036 shares worth $74.1M. The position accounts for 0.01% of the portfolio, ranked #1258.

Goldman Sachs first reported a position in PCVX in Q2 2020 and has held it in 23 quarters since. The position peaked at $256M in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Goldman Sachs held 1,275,036 shares of Vaxcyte worth $74.1M as of Q1 2026.
  • Goldman Sachs bought 196,916 Vaxcyte shares in Q1 2026, an estimated $10.7M.
  • Vaxcyte made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1258 holding.
  • Goldman Sachs first reported a position in Vaxcyte in Q2 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Vaxcyte position peaked at $256M in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.